Outlook Therapeutics receives FDA response on ONS-5010 for wet AMD
The ONS-5010 BLA resubmission was supported by data from the NORSE programme, including NORSE TWO and other trials.
Drug Development
Emmaus, NIT sign Endari distribution agreement
How one US state is tackling the drug affordability crisis
Johnson & Johnson acquires Halda Therapeutics for $3.05bn
Innovent receives NMPA approval for Tabosun colon cancer treatment
Gilead Sciences to acquire Repare’s RP-3467
Zydus and Bioeq partner for commercialisation of Nufymco in US
Genentech secures FDA approval for Lunsumio VELO SC for follicular lymphoma
